Yes, Memantine Can Cause Confusion
Confusion is a recognized adverse effect of memantine, occurring at a higher rate than placebo in clinical trials. According to FDA labeling, confusion is one of the most common adverse reactions (≥5% incidence and higher than placebo) in patients treated with memantine hydrochloride 1.
Evidence from Clinical Trials
In double-blind placebo-controlled trials involving 1,862 dementia patients (940 on memantine, 922 on placebo), confusion was specifically identified as one of four most common adverse reactions, alongside dizziness, headache, and constipation 1. This finding is consistent across multiple systematic reviews and meta-analyses.
The confusion associated with memantine is typically mild and transient 2, though this should not minimize clinical vigilance, particularly in vulnerable populations.
Clinical Context and Magnitude
A 2013 systematic review of 12 studies demonstrated that memantine significantly increased the risk of confusion compared to placebo 3. This is particularly important because:
- The baseline population already has cognitive impairment
- Distinguishing drug-induced confusion from disease progression can be challenging
- The effect appears dose-related and may be influenced by titration speed 2
Important Clinical Considerations
When initiating memantine, monitor closely for new or worsening confusion, especially during dose titration. The recommended titration schedule exists partly to minimize such adverse effects - starting at 5 mg daily and increasing weekly to the target dose of 20 mg/day 1.
Risk Factors to Consider:
- Severe renal impairment: Requires dose reduction to 5 mg twice daily, as decreased clearance increases plasma levels and potentially adverse effects 1
- Alkaline urine conditions: Can reduce memantine clearance by ~80%, leading to drug accumulation 1
- Combination therapy: Recent pharmacovigilance data suggests memantine combined with cholinesterase inhibitors shows disproportionate reporting signals for nervous system and psychiatric disorders 4
Practical Management
If confusion develops:
- Verify the patient wasn't already experiencing disease progression
- Check for conditions that raise urine pH (certain diets, carbonic anhydrase inhibitors, urinary tract infections) 1
- Assess renal function if not recently checked
- Consider slowing titration or temporarily reducing dose
- If confusion is severe or persistent, discontinuation may be necessary
The overall discontinuation rate due to adverse events with memantine (10.1%) is comparable to placebo (11.5%) 1, suggesting most adverse effects, including confusion, are manageable in clinical practice.